[Treatment with imatinib for refractory PAH].
Kazufumi
K
Nakamura
Satoshi
S
Akagi
Toshihiro
T
Sarashina
Aiko
A
Ogawa
Hiromi
H
Matsubara
Hiroshi
H
Ito
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D000077214:Becaplermin; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000235:genetics*; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D020574:Proto-Oncogene Proteins c-sis / Q000235:genetics / Q000502:physiology; D011651:Pulmonary Artery / Q000187:drug effects; D011668:Pulmonary Veno-Occlusive Disease / Q000188:drug therapy; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors; D014661:Vasoconstriction / Q000187:drug effects
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D020574:Proto-Oncogene Proteins c-sis; D011743:Pyrimidines; D000077214:Becaplermin; D000068877:Imatinib Mesylate; C099852:PDGF receptor tyrosine kinase; D017479:Receptors, Platelet-Derived Growth Factor